- Home
- IBRX vs SGHC Comparison
IBRX vs SGHC Comparison
Compare IBRX & SGHC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | IBRX | SGHC |
|---|---|---|
| Founded | 2014 | 2020 |
| Country | United States | Guernsey |
| Employees | N/A | N/A |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Services-Misc. Amusement & Recreation |
| Sector | Health Care | Consumer Discretionary |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 8.2B | 7.1B |
| IPO Year | 2015 | 2021 |
Fundamental Metrics
Financial Performance| Metric | IBRX | SGHC |
|---|---|---|
| Price | $8.08 | $13.98 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 7 | 6 |
| Target Price | $12.57 | ★ $17.33 |
| AVG Volume (30 Days) | ★ 8.5M | 2.3M |
| Earning Date | 05-08-2026 | 05-11-2026 |
| Dividend Yield | N/A | ★ 3.52% |
| EPS Growth | ★ 38.71 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $113,288,000.00 | N/A |
| Revenue This Year | $88.59 | $16.09 |
| Revenue Next Year | $131.15 | $9.73 |
| P/E Ratio | ★ N/A | $20.80 |
| Revenue Growth | ★ 668.31 | N/A |
| 52 Week Low | $1.95 | $8.46 |
| 52 Week High | $12.43 | $15.86 |
Technical Indicators
Market Signals| Indicator | IBRX | SGHC |
|---|---|---|
| Relative Strength Index (RSI) | 55.79 | 52.63 |
| Support Level | $6.68 | $13.19 |
| Resistance Level | $8.46 | $14.17 |
| Average True Range (ATR) | 0.33 | 0.34 |
| MACD | 0.08 | 0.12 |
| Stochastic Oscillator | 53.00 | 75.33 |
Price Performance
Historical ComparisonAbout IBRX ImmunityBio Inc.
ImmunityBio Inc is a biotechnology company focused on developing and commercializing next-generation immunotherapies designed to activate the patient's immune system and provide durable protection against cancer and infectious diseases. Its approach harnesses both the adaptive and innate immune systems with the Cancer BioShield platform. The platform is built around the proprietary IL-15 superagonist ANKTIVA (nogapendekin alfa inbakicept) and is supported by a portfolio that includes adenovirus-vectored vaccines, NK-cell therapies, and additional immunomodulators. The company operates in the United States and Europe, with the majority of its revenue coming from the United States.
About SGHC Super Group (SGHC) Limited
Super Group (SGHC) Ltd is a holding company that operates online sports betting and gaming businesses. The company's four operating segments-Betway, Spin, Jumpman and DGC. A majority of its revenue is generated from the Betway segment, which is a single-brand online sports betting and casino offering with licenses to operate throughout Europe, the Americas, and Africa. Spin is the company's multi-brand online casino offering, having a diverse portfolio of casino brands such as Jackpot City, Spin Casino, Dream Bingo, Mirror Bingo, etc., designed to be culturally relevant globally while aiming to offer a wide range of casino products. Geographically, the company generates maximum revenue from Africa and Middle East, followed by North America, Europe, Asia-Pacific, and South/Latin America.